<DOC>
	<DOCNO>NCT02590042</DOCNO>
	<brief_summary>A single-arm , open-labeled , single-center , descriptive exploratory safety trial use ADSC-SVF-002 . ADSC-SVF-002 autologous adipose derived stem cell ( ADSC ) -containing stromal vascular fraction ( SVF ) obtain subcutaneous fat harvest liposuction patient . As cellular therapy product , ADSC-SVF-002 ( fresh cryopreserved ) administer subcutaneously via injection , without unprocessed autologous fat ( fresh cryopreserved ) , soft tissue defect abnormally heal wound . The primary objective trial demonstrate safety ADSC-SVF-002 population subject soft tissue defect abnormal wound heal still symptomatic despite managed conventional therapy .</brief_summary>
	<brief_title>Safety Adipose-Derived Stem Cell Stromal Vascular Fraction</brief_title>
	<detailed_description>Protocol Number : SJS-CT-001 Phase : Pilot study Methodology : Open label , single-arm Study Duration : Six month accrual treatment last patient Study Center ( ) : Single-center Objectives : To demonstrate safety subcutaneous administration autologous ADSC-SVF-002 population subject soft tissue defect abnormal wound heal still symptomatic despite managed conventional therapy . Number Subjects : 10 Diagnosis Main Inclusion Criteria : Subject soft tissue deficiency , soft tissue post traumatic malformation , scar , and/or abnormal wound healing . Study Product , Dose , Route , Regimen : ADSC-SVF-002 . 1.0x106 cells/mL defect ( administer without fat ) 1.2x106 cells/mL defect ( administer fat ) . Subcutaneous injection . Duration administration : Administration product take approximately 30 minute . Administered . Reference therapy : N/A Statistical Methodology : Safety outcomes report descriptive statistic . Secondary ( efficacy ) outcomes assessed relative baseline ( screen ) follow : - For outcome assessed multiple follow-up visit , one-way ANOVAs follow Tukey 's test conduct - For outcome assessed one follow-up visit , Student 's t-test conduct . Data report mean Â± SD p &lt; 0.05 consider significant .</detailed_description>
	<criteria>1 . Subject soft tissue deficiency , soft tissue post traumatic malformation , scar , and/or abnormal wound healing . 2 . Subject adult male nonpregnant female age 18 80 year . 3 . Subject able undergo liposuction procedure opinion investigator per facility guideline . 4 . Subject able read , understand sign write Informed Consent participate study . 5 . Subject willing able comply study protocol , include requirement take abstaining medication . 1 . The subject woman childbearing potential ( surgically sterile postmenopausal least 1 year document medical history ) , use highly effective method contraception [ oral , injected implant hormonal method contraception ; intrauterine device ( IUD ) intrauterine system ( IUS ) ; condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository ; male sterilization ( vasectomy ) ] . 2 . Subject history cancer and/or know conditions/diseases prone malignancy . 3 . Subject significant cardiac , renal , hepatic failure disease may interfere ability interpret result study . 4 . Subject infection , cellulitis , osteomyelitis diagnose MRI microbiologic culture result . 5 . Subject autoimmune disorder . 6 . Subject connective , metabolic atrophic skin disease . 7 . Subject chronic anticoagulant therapy . 8 . Subject Body Mass Index ( BMI ) &gt; 30 . 9 . Subject positive HBs antigen , HCV antibody , HIV antibody . 10 . Subject receive investigational drug/drugs unapproved medication within 3 month registration study . 11 . Subject history hematopoietic stem cell transplantation radio immunotherapy . 12 . Subject recent significant weight loss , cause determine . 13 . Subject history hereditary link malignancy firstdegree relative ( parent , child , sibling ) . 14 . Subject participate another clinical trial within 6 week prior registration study . 15 . Subject psychiatric disorder judgment investigator could interfere provision inform consent , completion test , therapy , followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>